Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’
March 28, 2018 at 16:15 PM EDT
Sage Therapeutics has to balance two competing interests when it comes to pricing its postpartum depression drug, CEO Jeff Jonas says.